Nanopatches To Join The Fight Against Swine Flu
Main Category: Swine FluAlso Included In: Flu / Cold / SARS; Public Health; Respiratory / Asthma
Article Date: 15 Jul 2009 - 1:00 PDT
| Patient / Public: | ![]() |
5 (2 votes) |
| Healthcare Prof: | ![]() |
In response to the growing threat of swine flu, a UQ team is applying nanopatch technology to potentially solve the problems associated with vaccinating millions of Australians, thanks to a recently announced government grant.
Australian Institute for Bioengineering and Nanotechnology (AIBN) researcher Professor Mark Kendall heads a team testing the potency of mass vaccinations using only a fraction of the standard dose.
The project also targets cross-protection by delivering the seasonal vaccine to protect against challenge from the swine A H1N1 influenza virus.
Professor Kendall said this research used new nanopatch technology which does away with the needle and syringe and stimulated a potent immune response with a reduced dose.
"By accurately and reliably delivering the vaccine to the abundant immune cells, which are located just under of the surface of the skin, we are able to initiate a rapid and powerful immune response from the body, while using considerably less vaccine," Professor Kendall said.
"The beauty of the nanopatch is that it could enable large-scale rapid vaccinations in a cost effective manner that is currently not available with the needle and syringe.
"The nanopatch could also potentially eliminate needle phobia and the risk of needle stick injuries while being easy and cost-effective to administer" he said.
The team includes researchers from the University of Melbourne, the Australian Animal Health lab and one of Professor Kendall's UQ collaborators, Professor Ian Frazer of UQ's Diamantina Institute for Cancer Immunology and Metabolic Medicine.
The project is supported under the fast-tracked National Health and Medical Research Council's H1N1 (swine flu) Medical Research Projects.
Source
The University of Queensland
Visit our swine flu section for the latest news on this subject.
MLA
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/157502.php>
APA
http://www.medicalnewstoday.com/releases/157502.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




